Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study

Dong, Shu; Wang, L.; Guo, Ying; Hui, Ying; Shen, Xiaohui; Meng, Zhiqiang; Chen, Hao; Chen, Q. W.; Li, Z. S.

doi:10.1186/s12957-017-1175-7

Cited by 13 publications

(9 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, pancreatic adenocarcinoma (PDAC) is the most malignant subtype with a 5-year survival rate of less than only 5% [ 5 ]. Radical operation is the only way to cure PDAC, but over 85% of patients are already at advanced stages upon initial diagnosis that has lost the chance of radical resection [ 6 – 8 ]. Currently, coalition therapy combining surgery with chemotherapy, radiotherapy or immunotherapy is the main option in the clinic, however, PDAC is characterized by an extraordinary resistance to chemo- and radiotherapy as well as to molecularly targeted therapy and immunotherapy [ 9 – 17 ].…”

Section: Introductionmentioning

confidence: 99%

Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis

et al. 2020

View full text Add to dashboard Cite

Background Pancreatic adenocarcinoma (PDAC) is one of the most fatal malignancies. Surgical resection supplemented by chemotherapy remains the major therapeutic regimen, but with unavoidable resistance and systemic toxic reaction. Curcumin is a known safe natural compound that can effectively eliminate pancreatic adenocarcinoma cells in vitro, making it a promising candidate for substitution in subsequent chemotherapy. However, due to its extremely low bioavailability caused by its insolubility and circular elimination, curcumin had an unexpectedly modest therapeutic effect in clinical trials. Results Here, we electrospun curcumin/gelatin-blended nanofibrous mat to largely improve curcumin’s bioavailability by local controlled-release. With characterization by scanning electron microscopy, fluorescence microscopy, Fourier transform infrared spectroscopy, X-ray diffraction and high-performance liquid chromatography, it was revealed that curcumin was uniformly dispersed in the fiber of the mats with nanoscopic dimensions and could be continuously released into the surrounding medium for days. The cancer inhibitory effects of nano-curcumin and underlying mechanisms were further explored by assays using pancreatic adenocarcinoma cell and experiments using xenograft model. The results showed the released nano-curcumin could effectively inhibit pancreatic adenocarcinoma cell proliferation not only in vitro, but more importantly in vivo. This cytotoxic effect of nano-curcumin against pancreatic adenocarcinoma was achieved through provoking the production of intracellular reactive oxygen species and activating endoplasmic reticulum stress, which leads to enhanced cell apoptosis via decreased phosphorylation of signal transducer and activator of transcription 3. Conclusions Clinically, curcumin/gelatin-blended nanofibrous mat could be a promising, secure, efficient and affordable substitutional agent for the elimination of residual cancer cells after tumor resection. Moreover, our strategy to obtain curcumin released from nanofibrous mat may provide a universally applicable approach for the study of the therapeutic effects and molecular mechanisms of other potential medicines with low bioavailability.

show abstract

Section: Introductionmentioning

confidence: 99%

Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown some correlation between the clinical and pathological factors for the predisposition of liver metastasis in patients with PDAC 9,10. However, those reports were mainly based on small cohorts of patients and only evaluated fragmentary factors.…”

Section: Introductionmentioning

confidence: 99%

<p>Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study</p>

He¹,

Zhong²,

Cai³

et al. 2019

CMAR

View full text Add to dashboard Cite

Background: Few studies have explored the relationship between clinicopathological factors of patients with pancreatic ductal adenocarcinoma (PDAC) and liver metastasis. The aim of this study was to develop and validate a nomogram to predict liver metastasis in patients with PDAC. Patients and methods: Patients diagnosed with PDAC between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively collected. The nomogram was established based on a logistic regression model. The precision of the nomogram was evaluated and compared using concordance index (C-index), and the area under receiver operating characteristic curve (AUC). The clinical use of nomogram was evaluated by making use of a decision curve analysis (DCA). Results: A total of 12,644 eligible patients, which were randomly divided into training (n=9,483) and validation cohorts (n=3,161), were included in this study. The nomograms, which were established on the basis of independent predictors, were well calibrated, and demonstrated good discriminative ability, with C-indexes of 0.784 for the training cohort and 0.790 for validation cohort. The values of AUC for training and validation cohort were 0.792 and 0.800, respectively. When other sites of distant metastases were included into this predictive system, the new predictive model demonstrated a better discriminative ability and greater net benefit in predicting liver metastasis in patients with PDAC in both the training and validation cohorts. Conclusion: Nomograms were constructed to predict liver metastasis in patients with PDAC. Validation revealed excellent discrimination and calibration of the nomograms, suggesting that the nomograms were well calibrated and could serve to improve the prediction of the risks of liver metastasis which can be used to guide the management of patients with PDAC.

show abstract

“…Recently, Dong et al reported a retrospective study that included 1,787 advanced PDAC patients. 10 They demonstrated that both primary tumor location and diameter were significantly associated with the risk of synchronous liver metastasis. Tumor size, a powerful and reliable predictor of both distant metastasis and prognosis, 5,27 was found to have an intimate association with the infiltration of the pancreatic cancer cells into the liver.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown some correlation between the clinical and pathological factors for the predisposition of liver metastasis in patients with PDAC. 9,10 However, those reports were mainly based on small cohorts of patients and only evaluated fragmentary factors. It would be interesting to study the association between clinicopathological factors and liver metastasis, and to construct effective models to predict the risk of liver metastasis for patients with PDAC.…”

Section: Introductionmentioning

confidence: 99%

Development and Validation of a Nomogram to Predict Liver Metastasis in Patients with Pancreatic Ductal Adenocarcinoma: A Large Cohort Study

He¹,

Zhong

Cai³

et al. 2018

SSRN Journal

View full text Add to dashboard Cite

These authors contributed equally to this workBackground: Few studies have explored the relationship between clinicopathological factors of patients with pancreatic ductal adenocarcinoma (PDAC) and liver metastasis. The aim of this study was to develop and validate a nomogram to predict liver metastasis in patients with PDAC. Patients and methods: Patients diagnosed with PDAC between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were retrospectively collected. The nomogram was established based on a logistic regression model. The precision of the nomogram was evaluated and compared using concordance index (C-index), and the area under receiver operating characteristic curve (AUC). The clinical use of nomogram was evaluated by making use of a decision curve analysis (DCA). Results: A total of 12,644 eligible patients, which were randomly divided into training (n=9,483) and validation cohorts (n=3,161), were included in this study. The nomograms, which were established on the basis of independent predictors, were well calibrated, and demonstrated good discriminative ability, with C-indexes of 0.784 for the training cohort and 0.790 for validation cohort. The values of AUC for training and validation cohort were 0.792 and 0.800, respectively. When other sites of distant metastases were included into this predictive system, the new predictive model demonstrated a better discriminative ability and greater net benefit in predicting liver metastasis in patients with PDAC in both the training and validation cohorts. Conclusion: Nomograms were constructed to predict liver metastasis in patients with PDAC. Validation revealed excellent discrimination and calibration of the nomograms, suggesting that the nomograms were well calibrated and could serve to improve the prediction of the risks of liver metastasis which can be used to guide the management of patients with PDAC.

show abstract

Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study

Cited by 13 publications

References 39 publications

Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis

Topically applicated curcumin/gelatin-blended nanofibrous mat inhibits pancreatic adenocarcinoma by increasing ROS production and endoplasmic reticulum stress mediated apoptosis

<p>Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study</p>

Development and Validation of a Nomogram to Predict Liver Metastasis in Patients with Pancreatic Ductal Adenocarcinoma: A Large Cohort Study

Contact Info

Product

Resources

About